Arkema S.A. ARKAY recently started its new Pebax elastomer unit at the Serquigny facility in France. This new unit, constructed with cutting-edge industrial processes, can make both bio-circular Pebax Rnew and traditional Pebax elastomers. These innovative materials are widely utilized in sports equipment such as running shoes, soccer shoes and ski boots, as well as in electrical gadgets and other niche industries such as antistatic additives and medical devices. Arkema has beefed up its global manufacturing capacity for Pebax elastomers by 40% at the Serquigny plant to support its customers’ growth, especially in the sports and consumer goods markets. This presents a significant opportunity for Arkema to meet growing demand in existing and new applications while also enhancing its operations, as water usage at the facility will be decreased by around 25%. Arkema's portfolio of first-class solutions addresses the ever-increasing demand for innovative and sustainable materials, building on its unique combination of materials science knowledge. Arkema provides cutting-edge technology solutions to address difficulties such as new energies, water access, recycling, urbanization and mobility, and maintains open lines of communication with all of its stakeholders. Shares of Arkema have gained 7% over the past year against a 22.9% decline of its industry. Zacks Investment Research Image Source: Zacks Investment Research Zacks Rank & Key Picks Arkema currently carries a Zacks Rank #4 (Sell). Better-ranked stocks in the basic materials space include Cameco Corporation CCJ, Carpenter Technology Corporation CRS and Alpha Metallurgical Resources Inc. AMR. Cameco, carrying a Zacks Rank #1 (Strong Buy), has a projected earnings growth rate of 188% for the current year. The Zacks Consensus Estimate for CCJ’s current-year earnings has been revised upward by 12.5% in the past 60 days. The stock is up around 71.6% in a year. You can see the complete list of today’s Zacks #1 Rank stocks here. Carpenter Technology currently carries a Zacks Rank #1. CRS beat the Zacks Consensus Estimate in three of the last four quarters while matching it once, with the average earnings surprise being 12.2%. The company’s shares have soared 20% in the past year. The Zacks Consensus Estimate for AMR’s current-year earnings has been revised upward by 69% in the past 60 days. It currently carries a Zacks Rank #1. AMR delivered a trailing four-quarter earnings surprise of roughly 9.6%, on average. AMR shares are up around 125.6% in a year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alpha Metallurgical Resources, Inc. (AMR):Free Stock Analysis Report Carpenter Technology Corporation (CRS):Free Stock Analysis Report Cameco Corporation (CCJ):Free Stock Analysis Report Arkema SA (ARKAY):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Arkema (ARKAY) Unveils New Pebax Elastomer Unit in France
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...